Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The WavelinQ™ Arterio-Venous Endovascular Fistula: A Global, Multi-Center, Prospective, Post-Market, Confirmatory, Interventional, Investigation

NCT04626427 is registered in ClinicalTrials.gov with C. R. Bard as lead sponsor.

NCT NCT04626427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04626427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The WavelinQ™ Arterio-Venous Endovascular Fistula: A Global, Multi-Center, Prospective, Post-Market, Confirmatory, Interventional, Investigation
Lead sponsor
C. R. Bard
Phase
Not applicable
Overall status
Terminated
Start date
December 23, 2020
Completion date
June 15, 2022
Enrollment
21 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

av fistula, chronic kidney diseases, end stage kidney disease, fistulas arteriovenous, kidney disease, chronic, kidney failure, kidney insufficiency